CRISPR Therapeutics vs Editas Medicine
CRSP and EDIT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRSP and EDIT compare
CRISPR Therapeutics is the larger company, worth 12 times as much as Editas Medicine ($4.4B against $366M).
Editas Medicine grew revenue faster over the last twelve months (7.4% versus −34.3% for CRISPR Therapeutics).
Editas Medicine keeps more of each dollar of sales as profit, with a net margin of −145% compared with −1812% at CRISPR Therapeutics.
CRISPR Therapeutics scores higher on the StockData Score (8 against 3 for Editas Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRSP | EDIT |
|---|---|---|
| Size and price | ||
| Market cap | $4.4B | $366M |
| Share price | $45.75 | $2.38 |
| Change, 1 year | −16.2% | −5.6% |
| Change, 5 years | −44.5% | −93.3% |
| Beta (5Y) | 1.39 | 2.19 |
| Employees | 393 | 87 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 176× | 7.3× (better) |
| P/B | 2.7× (better) | 4.3× |
| FCF yield | −8.5% (better) | −30.2% |
| Fair value | – | $1.62 |
| Margin of safety | – | −47.2% |
| Growth | ||
| Revenue growth (TTM) | −34.3% | 7.4% (better) |
| Revenue growth, 5Y average | 37.3% (better) | −14.9% |
| Profitability | ||
| Operating margin | −2115% | −152% (better) |
| Net margin | −1812% | −145% (better) |
| FCF margin | −1497% | −222% (better) |
| Return on equity | −25.6% (better) | −147% |
| Financial health | ||
| Debt / equity | 0.00 | 0.67 (better) |
| Interest coverage | – | −10.6× |
| Current ratio | 16.21 (better) | 2.82 |
| Altman Z-score | 2.01 (better) | −9.39 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −2.5% (better) | −36.6% |
| Shareholder yield | −2.5% (better) | −36.6% |
| Ownership | ||
| Held by institutions | 78.9% | 78.3% |
| Held by insiders | 2.7% | 0.45% |
| Insider net buying, 12 months | −$17.9M | −$107K (better) |
| Short interest, % of float | 18.3% | 25.3% |
Go deeper
- CRSP stock overview
- CRSP income statement
- CRSP valuation and score
- EDIT stock overview
- EDIT income statement
- EDIT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.